A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

about

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

Item

http://www.wikidata.org/entity/Q37107776

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

@en

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes.

@nl

type

Item

label

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

@en

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes.

@nl

prefLabel

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

@en

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes.

@nl

P1476

A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes

@en

P2093

Hongli Shi

http://www.w3.org/2001/XMLSchema#string

Kuixiang Huang

http://www.w3.org/2001/XMLSchema#string

Ruizhen Ren

http://www.w3.org/2001/XMLSchema#string

Shaoling Zhou

http://www.w3.org/2001/XMLSchema#string

Shuyan Wang

http://www.w3.org/2001/XMLSchema#string

Weikai Hou

http://www.w3.org/2001/XMLSchema#string

Xiaomei Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Global estimates of the prevalence of diabetes for 2010 and 2030

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

Transcript Expression Data from Human Islets Links Regulatory Signals from Genome-Wide Association Studies for Type 2 Diabetes and Glycemic Traits to Their Downstream Effectors.

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.

Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?

Genetics of non-insulin-dependent (type-II) diabetes mellitus.

Phasic insulin release and metabolic regulation in type 2 diabetes.

Loss of early insulin secretion leads to postprandial hyperglycaemia.

Pancreatic beta-cell loss and preservation in type 2 diabetes.

Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy.

P304

1097-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2016.3394

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27446326

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4950570

http://www.w3.org/2001/XMLSchema#string